New solid-tumor research highlighted mechanisms that can blunt treatment effectiveness and sustain growth. In British Journal of Cancer, investigators reported that TP53 mutations push CD8+ T cells toward exhaustion in urothelial carcinoma, reshaping the tumor immune microenvironment and contributing to therapy resistance. In parallel, Cell Death Discovery research implicated PRMT6 as a driver of blood vessel growth in colorectal cancer, pointing to angiogenesis as another tractable lever. Both findings add molecular detail to how tumors manipulate immune function and supply. While still preclinical/biological at this stage, the results support ongoing interest in target discovery that can be paired with existing modalities—especially in cancers with limited durable responses.